Biotech Stocks Mostly Lower (Discovery Laboratories, Gilead Sciences, Affymax, Celsion Corporation)

Lakeway, TX -- (SBWIRE) -- 02/15/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Discovery Laboratories, Inc. (NASDAQ:DSCO) fell 1.50% and is trading at $2.63. Discovery Laboratories, Inc. is a biotechnology company focused on creating life-saving products for critical care patients with respiratory disease. The Company’s produces a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for normal respiratory function and survival.

How Should Investors Trade DSCO After The Latest Earnings Report? Find Out Here

Gilead Sciences, Inc. (NASDAQ:GILD) is lower 0.65% and is trading at $41.33. Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions.

Is GILD a Buy After The Solid Earnings? Get Free Trend Analysis Here

Affymax, Inc. (NASDAQ:AFFY) added 4.32% and is trading at $16.42. Affymax, Inc. is a biopharmaceutical company engaged in developing drugs to improve the treatment of serious and often life-threatening conditions. Its product candidate, peginesatide, is for the treatment of anemia in chronic kidney disease patients on dialysis.

How Should Investors Trade AFFY After The Recent Movement? Find Out Here

Celsion Corporation (NASDAQ:CLSN) is lower 1.52% and is trading at $1.30. Celsion Corporation is an oncology drug development company focused on the development of treatments for those suffering with difficult to treat forms of cancer. As of December 31, 2011, the Company's product ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer (the HEAT study), a Phase II clinical trial for colorectal liver metastasis (CRLM) and a Phase II clinical trial for recurrent chest wall breast cancer.

Get Latest News, Updates and Reports For Free On CLSN Here

About bestdamnpennystocks.com
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.